A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis
Standard
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis. / Weisel, Katja; Sonneveld, Pieter; Spencer, Andrew; Beksac, Meral; Rizzo, Maria; Xu, Yingxin; Fahrbach, Kyle; Gaudig, Maren; Slavcev, Mary; Dearden, Lindsay; Lam, Annette.
in: LEUKEMIA LYMPHOMA, Jahrgang 60, Nr. 1, 01.2019, S. 151-162.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis
AU - Weisel, Katja
AU - Sonneveld, Pieter
AU - Spencer, Andrew
AU - Beksac, Meral
AU - Rizzo, Maria
AU - Xu, Yingxin
AU - Fahrbach, Kyle
AU - Gaudig, Maren
AU - Slavcev, Mary
AU - Dearden, Lindsay
AU - Lam, Annette
PY - 2019/1
Y1 - 2019/1
N2 - Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiD-free regimens, including bortezomib and dexamethasone (Vd)-based treatments, and to explore differences in patient outcomes. The SLR identified 52 articles, from which four trials were ultimately included in the base-case NMA. The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens.
AB - Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiD-free regimens, including bortezomib and dexamethasone (Vd)-based treatments, and to explore differences in patient outcomes. The SLR identified 52 articles, from which four trials were ultimately included in the base-case NMA. The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens.
KW - Journal Article
U2 - 10.1080/10428194.2018.1466392
DO - 10.1080/10428194.2018.1466392
M3 - SCORING: Journal article
C2 - 30407092
VL - 60
SP - 151
EP - 162
JO - LEUKEMIA LYMPHOMA
JF - LEUKEMIA LYMPHOMA
SN - 1042-8194
IS - 1
ER -
